Innovative Diagnostic Platform Entopsis has developed a proprietary, cost-effective molecular profiling platform, including products like OpsisDx for urine-based cancer and disease diagnosis, which presents significant market opportunities in personalized medicine and at-home diagnostic testing.

Recent Product Expansion The launch of PlantOpsis in 2021 indicates the company's strategic move into plant testing and agriculture, opening avenues for partnerships and sales in the agricultural biotechnology sector focused on crop health and sustainability.

Disruptive Technology Awards Recognition such as the 2016 Most Disruptive Technology Award enhances credibility for Entopsis, making it attractive for collaborations, early adopter clients, and investors interested in cutting-edge biotech innovations.

Digital and Mobile Development Ongoing development of a smartphone app for at-home disease diagnosis creates opportunities for consumer-oriented sales channels, telehealth partnerships, and direct-to-consumer marketing efforts.

Funding and Revenue Potential With current revenues between 1M and 10M and a recent funding milestone of 1M, Entopsis is positioned for growth, offering sales teams scalable opportunities across diagnostic and biotech markets, especially those interested in emerging, disruptive health technologies.